Inhibikase Therapeutics第二季度每股收益$（0.11）错过$（0.09）估计

Inhibikase Therapeutics (NASDAQ: IKT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 83.33 percent increase over losses of $(0.66) per share from the same period last year.